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Abstract
al-Antitrypsin (alAT) deficiency is a hereditary disorder as-
sociated with reduced serum alAT levels and the development
of pulmonary emphysema. An alAT gene is defined as "Null"
when no alAT in serum is attributed to that alAT gene. Al-
though all alAT Null genes have identical phenotypic conse-
quences (i.e. no detectable alAT in the serum), different geno-
typic mechanisms can cause the Null state. This study defines
the molecular basis for the alAT gene Nullf,,,,, identified
and cloned from genomic DNA of an individual with the Null-
Null phenotype and emphysema resulting from the heterozy-
gous inheritance of the Nullm.,w, and Nullb.Iuigm genes. Se-
quencing of exons Ic-V and all exon-intron junctions of the
Null",,Vt. gene demonstrated it was identical to the common
normal Ml(Va1213) alAT gene except for the insertion of a
single nucleotide within the coding region of exon V, causing a
3' frameshift with generation of a premature stop signal. Fam-
ily analysis using oligonucleotide probes specific for the
Nullmt,. sequence demonstrated the gene was inherited in an
autosomal fashion. Examination of blood monocytes demon-
strated that a normal-sized, 1.8-kb alAT mRNA transcript is
associated with the Nul1tf,1,. gene and in vitro translation of
mRNA with the Null.,,,, mutation showed it translated at a
normal rate but produced a truncated alAT protein. Addition-
ally, retroviral transfer of the alAT Nulls wa cDNA to mu-
rine fibroblasts demonstrated no detectable intracellular or se-
creted alAT, despite the presence of alAT Null,,twa mRNA
transcripts. These findings are consistent with the concept that
the molecular pathophysiology of Nullf,,wa is likely mani-
fested at a posttranslational level. The identification of the
Null~t.,,, gene supports the concept that Null a1AT alleles
represent a heterogenous group in which very different mecha-
nisms cause the identical phenotypic state.
Introduction
al-antitrypsin (alAT)' deficiency is an autosomal hereditary
disorder, characterized in adults by reduced serum a 1AT
levels and the development ofpulmonary emphysema by ages
30-45 (1, 2). With the knowledge that the major physiologic
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1. Abbreviations used in this paper: alAT, al-antitrypsin; DLCO,
diffusing capacity; FEV,, forced expiratory volume in one second;
FVC, forced vital capacity; TLC, total lung capacity.
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role of a lAT is to inhibit neutrophil elastase, we understand
that the pathogenesis ofthe emphysema associated with aIAT
deficiency results from insufficient alAT, which provides the
lower respiratory tract protection against the chronic burden
of elastase in the local milieu (3, 4). As a result, over several
decades, there is progressive destruction of the alveolar walls,
culminating in the clinical disorder, emphysema.
alAT is coded for by a single copy gene of 12.2 kb on
chromosome 14 at q31-32.3 (5-7). The coding exons of the
gene are highly pleomorphic, with > 75 alleles described (1, 8,
9). The alAT phenotype is determined by codominant ex-
pression ofthe parental alleles (1, 8, 10). The aIAT deficiency
state associated with emphysema occurs only when there are
abnormalities in both ofthe parental genes (8, 10, 1 1). In most
cases there is some a 1AT detectable in serum, albeit in re-
duced amounts (1, 2, 8, 11). For example, the commonest
form of alAT deficiency associated with emphysema results
from the homozygous inheritance of the Z allele, a circum-
stance that results in aIAT serum levels 10-15% of normal (1,
8, 1 1). There are also alAT genes causing an absolute defi-
ciency state (1O, 12-23). This category ofaIAT genes, referred
to as the Null alleles, represents alAT genes in which the gene
is present but does not code for an a 1AT molecule that is
detectable in the serum (1O, 19). Compared with the deficiency
alleles, the Null genes are rare, with an estimated allelic fre-
quency of < 0.001 in Caucasians of Northern European de-
scent (13). Although all Null alleles were originally thought to
be similar, it is now recognized that the alAT gene can be
rendered Null by different mutations (21-23). The purpose of
this study is to demonstrate a newly recognized type of muta-
tional event that can cause the a 1AT Null state, Nullmaw,,w. a
nucleotide insertion in a coding exon, causing a 3' frameshift
with generation of a stop signal many codons distal to the
mutation. Interestingly, unlike Nullbe,,innm, in which a stop
codon is associated with a lack of detectable alAT mRNA in
a I AT-synthesizing cells, the Nullma,,,wa gene codes for detect-
able a IAT mRNA, but no detectable a lAT protein produced
by these cells.
Methods
Identification ofthe Null-Null phenotype in two index cases. The Null-
Null alAT phenotype was identified in two sisters (index case 1 and
index case 2) using a combination of isoelectric focusing of serum at
pH 4-5 to identify alAT alleles, serum alAT levels (radial immuno-
diffusion), and family analysis (Fig. 1) (10). To confirm that the index
cases were truly Null-Null, the serum was also evaluated for the pres-
ence of aIAT using an enzyme-linked immunoassay sensitive to 2
nM2 (24). The two index cases both had clinical evidence of emphy-
sema.
2. a 1 AT levels expressed in milligrams per deciliter are based on the
commonly used commercial standard, whereas those in micromolar
are based on a true laboratory standard; the commercial standard
overestimates aIAT levels by 35% (see reference 24 for details).
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Figure 1. Family tree demonstrating
M2 Null Ml Null the inheritance of Null alleles.
147 129 a AT phenotypes were determined
by evaluating the alAT patterns in
isoelectric focusing of serum, alAT
levels in serum, and family analysis.
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Index case 1, a 39-yr-old female who had had dyspnea for 10 yr,
had no smoking history. Severe pulmonary emphysema was docu-
mented by physical examination showing a hyperresonant chest and
distant breath sounds; chest x ray demonstrating hyperinflation, flat-
tened hemidiaphragms, and a marked loss ofvascularity at both bases;
xenon-127 ventilation scan showing abnormal retention of gas in the
lower lobes and a technetium-99m perfusion scan depicting loss of
vascularity in the same regions; pulmonary function testing (25) re-
vealing that vital capacity (VC) was 42% predicted, total lung capacity
(body plethysmography) was 122% predicted, forced expiratory vol-
ume in 1 s (FEVI) was 25% predicted, FEV1/forced (F) VC was 50%
observed (69% predicted value), and diffusing capacity (DLCO; cor-
rected for volume and hemoglobin) was 41% predicted.
Index case 2, a 31-yr-old female without pulmonary symptoms,
had no smoking history. The physical examination and chest x ray
were normal. The presence of mild emphysema was documented by a
xenon-127 ventilation scan demonstrating abnormal retention of gas
in the lower lobes, a technetium-99m perfusion scan showing comple-
mentary loss of vascularity, and lung function testing revealing VC was
93% predicted, TLC was 114% predicted, FEVI was 78% predicted,
FEV1/FVC was 65% observed (82% predicted), and DLCO was 87%
predicted.
Evaluation ofgenomic DNA using oligonucleotide gene probes. To
determine if the Null-Null phenotypes of the index cases were due to
the inheritance of the alAT Null alleles Nullbellingham (21) or
NUllgrnit, fll. (22), genomic DNA of the index cases and relevant con-
trols were evaluated using gel hybridization with oligonucleotide gene
probes by the method of Kidd et al. (26) as modified by Satoh et al.
(21). Genomic DNA ofindex case 1, a normal M1(Val2I3) homozygote
(27), a Nul1eii,,jam homozygote, and an Ml (Val213) Nullg,,ite fajls het-
erozygote were digested with the restriction endonuclease Pst I and the
DNA was electrophoresed on 0.7% agarose (8 ;ig/lane). The gels were
hybridized at 55°C with oligonucleotide gene probes centered on the
sequence of interest (see Fig. 2, top for the sequences used). The oligo-
nucleotide probes were 5'-labeled with [32P]ATP and separated from
unincorporated label on an 8% polyacrylamide-8 M urea denaturing
gel. After hybridization, the gels were washed at 60°C in 25 mM
sodium phosphate buffer, pH 7.0, 0.45 M NaCl, 2.5 mM EDTA, 0.1%
SDS for 15 min and autoradiographed at -70°C for 2 wk.
Cloning and sequencing ofthe Nullmnaawa gene. After oligonucleo-
tide analysis of genomic DNA of index case 1 demonstrated that the
Null-Null state in this family was caused by inheritance of the
Nullbjiji&m allele together with a previously unidentified Null allele
(referred to subsequently as NulImaI..tt based on the birthplace ofindex
case 1). The NullmatItw. gene was cloned from genomic DNA of index
case I by conventional methods. Using DNA from skin fibroblasts, a
cosmid library was prepared by inserting size-fractionated partial
Mbo I-digested DNA into the vector C2RB (28) with subsequent
packaging and transfection into Escherichia coli 1046 as previously
described by van Ommen et al. (29). The primary library was plated
out on 20 90-mm dishes at a density of 40,000 colonies per dish.
Duplicate filters were prepared and the filters hybridized under stan-
dard conditions using a 32P-labeled human a 1AT cDNA probe. Clones
containing the region of the aIAT gene were confirmed by restriction
enzyme analysis using Eco RI. To select for the Nullmanawa allele, cos-
mid clones containing the a IAT gene were evaluated using oligonucle-
otide gene probes as described above. Because the genotype of index
case 1 had been defined as heterozygous Nullbiiingham Nullmattawa, those
clones which did not contain the NUllbelfinam sequence at residue 217
by definition contained the Nullmatta, allele. A single 40-kb cosmid
clone that contained the entire alAT Nullmatt,,. gene plus flanking
regions was selected and subcloned into pUC19 by standard tech-
niques (30). The recombinant subclones obtained contained 0.5 kb
encompassing exon Ic, 1.6 kb encompassing exon II, 2.4 kb encom-
passing exons III and IV, and 1.1 kb encompassing exon V (see Fig. 2,
top, for the overall normal a 1AT gene structure). These subclones were
used as templates for sequencing using the dideoxynucleotide chain
termination method (31) with bidirectional primers of 1 5-mer oligonu-
cleotides (30). Sequencing included 150 bp 5' to exon Ic, exons Ic-V
together with the intron-exon junctions, and 40 bp 3' to exon V.
Demonstration of inheritance of the Nu11,na,,awa allele. To demon-
strate the inheritance of the Nullmatwa,8 mutation, oligonucleotide
probes were prepared that were complementary to both the region
centered at residue 353 in exon V with the insertional mutation in
Nullmawa and to the normal sequence in this region. Genomic DNA
from index case 1, index case 2, the father of the index cases, and an
Ml(Val213) homozyogote control were cut with Pst I and evaluated
with labeled oligonucleotide probes using the methods described
above.
Evaluation of aJAT mRNA transcripts from cells expressing the
aJAT gene. To gain insight into the consequences of the NuIlman,,a
mutation, blood monocytes, cells known to normally express the
alAT gene (32, 33) were evaluated for the presence of alAT mRNA
transcripts. Monocytes were evaluated from index case 2 and com-
pared with those from a normal MI(Val2'13) homozygote control. Al-
though index case 2 (like index case 1) is a Nullbninom-Nullmanawa
heterozygote, the consequences of the Nullmata, allele could be di-
rectly evaluated independent of the Nullbeffinham allele because (a) the
parental a1AT genes are codominantly expressed, i.e., a1AT gene
expression ofone allele is independent ofthe other parental allele (1, 8,
10); and (b) the Nullbifingham gene is known to be associated with no
a IAT mRNA transcripts and no production ofa IAT by blood mono-
cytes (20).
Blood monocytes were isolated from index case 2 and a normal
M 1 (Val2"3) homozygote using adherence purification of mononuclear
cells obtained by monocytapheresis. Blood mononuclear leukocytes
were harvested by cytapheresis on a cell separator (model 2297; IBM
Instruments, Inc., Danbury, CT) during continuous centrifugation by
standard techniques (34). The mononuclear cells were separated from
contaminating granulocytes using Hypaque-Ficoll density centrifuga-
tion. The resulting mononuclear cells were resuspended in DMEM
supplemented with 10% FCS (Biofluids) and allowed to adhere to
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150-mm tissue culture plates for 1 h at 370C. The nonadherent cells
were removed and the plates were washed three times with PBS, pH
7.4. The resulting adherent cells were harvested by scraping, washed
three times, with PBS, and replated as above. The resulting cell popula-
tions were > 90% monocytes (morphology and nonspecific esterase
staining) and had > 95% viability (trypan blue exclusion). alAT
mRNA transcripts in the monocytes were evaluated by Northern anal-
ysis (33). Total cellular RNA (10 ,Ag/lane) prepared by guanidine HCl
extraction followed by CsCl centrifugation was electrophoresed in aga-
rose gels under denaturing conditions, transferred to nitrocellulose
filters, hybridized with a 32P-labeled alAT cDNA probe, and autora-
diographed.
Analysis of translation of NUilmattawa aJAT mRNA transcripts. In
vitro translation analysis was used to examine the effect of the
Nullmat.awa mutation on the translation of the alAT mRNA transcript
into protein. To accomplish this, an a 1 AT Nullmat.awa cDNA was con-
structed from a normal alAT Ml(Val2"3) cDNA (pPBO1) by standard
techniques. Both this mutant alAT cDNA and a normal Ml(Val213)
aIAT cDNA were used to construct plasmids for use in the Riboprobe
(Promega-Biotec) SP6 polymerase in vitro transcription system. The
M l(Val213) a1AT cDNA containing plasmid and the Nullmant,. alAT
cDNA containing plasmid served as templates for generation of
capped, poly-adenylated synthetic alAT mRNA transcripts of normal
MI(Val213) type or mutant Nullmantwa type, respectively (35). After
purification, 1 ,ug of each alAT mRNA species was used to direct
translation (1 h at 37°C) in a rabbit reticulocyte lysate system (Pro-
mega-Biotec) with [35S]methionine used as a label. Aliquots of the
reaction mixtures were analyzed by SDS-acrylamide gel electrophore-
sis and fluorography and quantified by laser densitometry.
Retroviral gene transfer ofhuman MJ(Val213)-type and Null,,xtawav
type alAT cDNAs. To examine posttranslational events in a lAT bio-
synthesis, Ml(Val2 3) and Nullmatawa type alAT cDNAs were trans-
ferred to murine fibroblasts using retroviral gene transfer. The retro-
viral vectors used to insert the full length M l(Val213)-type and
Nullma.,,a-type alAT cDNAs into the genome of mouse fibroblasts
were constructed from the N2 vector as previously described (36). The
final retroviral vectors (pN2-a lAT/M l and pN2-a lAT/Mattawa)
contained (5' to 3') the SV40 early promoter and full length human
alAT cDNAs ofMl(Val213) type or NUllmatawa type, respectively, in-
serted into the Xho I site of N2. Sequence analysis confirmed that
pN2-alAT/Mattawa differed from pN2-alAT/Ml by only the single
nucleotide insertion corresponding to the Nullmatwa mutation. The
helper virus-free packaging cell line 0t2 (37) was used to package tran-
scripts from pN2-alAT/Ml and pN2-a1AT/Mattawa into ecotropic
infectious viral particles that were then used to infect NIH-3T3 cells.
Polyclonal populations ofinfected NIH-3T3 cells were scored at > 100
colonies/10-cm plate and were equivalent for the human alAT
Ml(Val2'3)-type and Nullmat5,wa-type cDNA containing cell popula-
tions, referred to as NIH-3T3/alAT-Ml and NIH-3T3/alAT-Mat-
tawa, respectively.
alAT mRNA levels in mouse fibroblasts. Human alAT mRNA
transcripts were identified in NIH-3T3/alAT-M 1 and NIH-3T3/
alAT-Mattawa cells by cytoplasmic dot hybridization (38). Unin-
fected NIH-3T3 cells were used as control. Extracted cytoplasmic
RNA was denatured and applied to nitrocellulose filters with a mini-
fold apparatus (Schleicher & Schuell, Keene, NH) in serial dilutions.
The filters were hybridized using a 32P-labeled human alAT cDNA
probe. Exposure of the autoradiograms was for 48 h at -70°C.
Synthesis and secretion ofhuman alAT by mouse1ibroblasts. The
synthesis and secretion of human alAT by NIH-3T3/alAT-Ml and
NIH-3T3/alAT-Mattawa cells was evaluated by immunoprecipita-
tion of [35S]methionine-labeled alAT as previously described (36).
NIH-3T3/alAT-Ml and NIH-3T3/alAT-Mattawa cells were plated
(5 X 105 cells per 60-mm plate); the next day, each plate was incubated
for 10 min in methionine-free Iscove's minimal essential medium
containing 10% dialyzed calf serum, pulsed with 250 ,uCi of [35S]-
methionine (600 Ci/mmol) for 30 min, then chased with nonselective
media supplemented with 1 mM unlabeled methionine for 120 min.
To normalize the two study cell populations, aliquots of supernatants
containing I05 dpm and lysates containing 106 dpm of TCA-precipita-
ble protein were compared. Immunoprecipitation, gel electrophoresis,
and fluorography were as previously described (33).
Results
Evaluation of index case I for the presence ofthe Nullgraniie falls
and the NUllbellingham alleles. Using oligonucleotide probes spe-
cific for the sequence defining the Nulluanite falls mutation, the
Nullbellingham mutation, and the corresponding normal se-
quences of these regions, it was apparent that the a 1AT geno-
type ofindex case 1 was heterozygous Null-Null containing the
Nullbeillingham mutation at one allele and a different alAT Null
mutation in the other allele (Fig. 2). In this regard, genomic
DNA of index case 1 had a sequence that was normal in the
regions defining the NU11granite falls mutation (compare lane 6
with lane 5, along with the controls in lanes 1-4). In contrast,
the genomic DNA of index case 1 clearly contained the
Nullbellingham mutation in one gene (lane 12), and a normal
sequence in the Nullbeingham mutation region in the other (lane
11, along with controls lanes 7-10). Together, these findings
indicate that index case 1 must be a heterozygous Null-Null,
with one Nullbeingham allele and another, different a lAT Null
allele, which possesses the normal sequence at positions
214-220 (the region of the Nullbellingham mutation).
Identification ofthe Nuilmattawa mutation by sequence analy-
sis. Sequencing of exons Ic-V, all exon-intron junctions, and
the 3' flanking region of the cloned a1AT Nullmatawa gene of
index case 1 demonstrated that it was identical to that of the
normal Ml (Val2'3) a1AT gene except for a single nucleotide
insertional mutation in the exon V coding region at residue
353 of the primary amino acid sequence (Fig. 3). The 217
region of the Nullmattawa allele, the region of the Nullbellingham
mutation site, was similar to the normal a1AT Ml(Val213)
gene. This novel mutation causes a 3' frameshift, resulting in
an altered reading frame commencing at the codon for amino
acid 353. The new nucleotide sequence codes for a signifi-
cantly altered amino acid sequence distal to the insertion site
and terminates in a premature stop signal at new codon 376.
Demonstration ofinheritance ofthe NUilmattawa gene. Evalu-
ation ofgenomic DNA of the index cases and the father ofthe
index cases using synthetic oligonucleotide probes centered at
the 353 region and specific for the NUllmatawa mutation se-
quence or the corresponding normal sequence, demonstrated
that the NUllmatuawa nucleotide insertion mutation had been
inherited in an autosomal fashion (Fig. 4). In this context,
specific hybridization of the Nullmatawa probe to the genomic
DNA of index case 1 (lane 2), index case 2 (lane 4), and the
father (lane 6), yielded a 1.1-kb band corresponding to the Pst I
fragment containing the mutated sequence in exon V. Geno-
mic DNA of both index cases and the father also specifically
hybridized with the normal 350-356 probe. In the case of the
father, the alternate allele is M2 (Fig. 1) and thus is identical to
the normal probe in the 350-356 region. Likewise, even
though both index cases have the Nullbellingham allele as the
alternate allele, they are normal in the 350-356 region (the
Nullbiingham substitution mutation is centered at residue 217).
Based on this analysis, it may be deduced that the genotype of
the mother isM lNullbeiingam despite the lack ofdirect analysis
of her DNA. Together, these observations confirm both the
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Figure 2. Evaluation of index case 1 for the presence of two previously described Null alleles, Null.gnit5 fails (22) and Nullb,1ingh..m (21). The oligo-
nucleotide gene probes used included: probes centered on the NU11gnit fails defect (Nullgf) or the corresponding normal sequence for residues
157-164 (Normal,57-164) and probes that centered on the Nullmiin,,m defect (Nullb) or the corresponding normal sequence for residues 214-220
(Normal2l4 220). Shown at the top is the structure of the aIAT gene. Exons IA-k contain untranslated regions (for hepatocyte alAT expression,
the 3' part of exon Ic and a short 5' segment of exon II; for mononuclear phagocyte expression, IA, B1, Ic and a short 5' segment of exon II; see
references 6, 7, and 9), whereas the coding regions for the protein are in exons II-V (6). Both the sequences of the oligonucleotide probes and
the corresponding coded amino acids in the primary protein structure are depicted; the mutational changes are underlined. The probes were la-
beled and used to evaluate Pst I- (P) digested genomic DNA from various sources; Pst I was used because it separates the exons with the Null-
granite falls and Nullbellingham mutations (see diagram and text). Lane 1, genomic DNA of an MIl(Val213) homozygote control evaluated with Nor-
Mal,57164 probe. Lane 2, identical to lane I except evaluated with Nullgranite falls probe. Lane 3, genomic DNA of Ml (Val213) Nullgrt falls hetero-
zygote evaluated with Normal,57-164 probe. Lane 4, identical to lane 3 except evaluated with Nullg,.,,ie falls probe. Lane 5, genomic DNA of index
case I (see Fig. 1) evaluated with Normal157 164 probe. Lane 6, identical to lane 5 except evaluated with Null.je,,falls probe. Lane 7, genomic
DNA of an MIl(Val2'3) homozygote control evaluated with Normal214220 probe. Lane 8, identical to lane 7 except evaluated with
Nulhb,jinglam probe. Lane 9, genomic DNA of Nulljignm homozygote evaluated with Normal214220 probe. Lane 10, identical to lane 9 except
evaluated with Nullbeiingham probe. Lane 11, genomic DNA of index case I evaluated with Normal214220 probe. Lane 12, identical to lane 11 ex-
cept evaluated with Nullbeingham probe.
autosomal inheritance of the NUllmaa allele in this family
and the heterozygous Nullbelingham-Nullmatawa phenotype ofthe
index cases.
Evaluation ofalA T-producing cells for mRNA transcripts
associated with the Nuilmatawa gene. Because the Nullbeeffio.
allele is associated with the complete absence ofa1AT mRNA
in alAT producing cells (20), any alAT mRNA transcript
exhibited by blood monocytes ofthe index case must represent
the exclusive expression of the Nullma.,,, allele. In this regard,
Northern analysis ofRNA of index case 2 showed that a 1AT
mRNA transcript was expressed (Fig. 5). Furthermore, it was
1.8 kb long (lane 2), similar to the alAT mRNA transcripts of
a normal Ml(Val213) homozygote (lane 1). It appears, there-
fore, that the presence of a stop codon near the 3' end of the
a 1AT mRNA molecule generated by the Nullmatt,,, mutation
is not associated with the absence of alAT mRNA as is the
case for the Nullinghanm mutation, in which the stop signal is
generated near the center of the coded aIAT mRNA.
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Figure 3. Identification of Nullmatt,,, mutation in exon V by sequence analysis. (A) Schematic representation of the alAT gene, see legend to
Fig. 2 for details. The Pst I (P) subclones used for sequencing are indicated above the gene; the actual areas sequenced are shown as solid lines
below the gene. The sequence was identical to that of the aIAT Ml(Val2'3) gene except for a region in exon V. (B) Evaluation of the 348-356
region of exon V for the Ml(Val213) and Nullma.,,w alleles. A thymidine insertion (arrow) in the codon for amino acid 353 is the single change
in the Nullmat,. allele. (C) The nucleotide insertion in codon 353 causes a frameshift in the 3' direction, which alters the reading frame and
generates a stop signal at the new codon 376.
Translation ofthe Nuilmatawa alATmRNA transcript. Eval-
uation of the translation of the Nullmatwa a IAT mRNA tran-
script demonstrated that it was capable ofdirecting the synthe-
sis of an a lAT protein product in a fashion comparable to the
normal Ml(Val213) alAT mRNA transcript, except that, as
expected for a mutation causing a stop codon, the translation
product was truncated (Fig. 6). In this context, in vitro trans-
lation of a synthetic a lAT Ml(Val213) mRNA transcript di-
rected synthesis of a 47-kD aIAT protein species (lane 1),
corresponding to the nonglycosylated a lAT protein including
the 24-amino acid signal peptide. In contrast, the a AT
Nullma.tawa mRNA transcript directed the synthesis of a 45-kD
a IAT protein species (lane 2), corresponding to the primary
translation product of aIAT minus the 19 amino acids 3' to
the premature termination codon of the NUllmattawa gene that
are not translated into protein. Quantification of the amounts
of alAT directed by the Nullmaawa mRNA demonstrated it
was similar to that directed by the normal mRNA (P > 0.2;
two-tailed t test). It thus appears that the insertional mutation
of the Nullmattawa gene does not alter the capacity of the
Nullm.,twa mRNA transcript to be translated into protein and
that, therefore, the molecular pathophysiology accounting for
the aMAT Null state associated with this gene is likely not
manifest at the translational level.
Human alA T gene expression in murinejibroblasts modi-
fied to contain the human aJAT of MJ(Val213)-type and
Nullmtawa-type cDNAs. Retroviral gene transfer of the human
alAT cDNAs of the normal Ml(Val2'3)-type and the mutant
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Figure 4. Determination of the in-
heritance of the Nullma,,awa allele
using an oligonucleotide probe spe-
cific for the NUilmattawa mutation.
Synthetic 21 -mer oligonucleotide
probes centered in exon V about the
NUilmattawa mutation (Nullm) or the
corresponding normal sequence in
the region coding for residues
350-356 (Normal350356) were used
to evaluate genomic DNA. Shown
are the sequences of the probes and
the corresponding coded amino acid
sequence of the primary protein
structure. The nucleotide insertion
in Nullmattaw is underlined. Geno-
mic DNA was digested with Pst I
(P), an enzyme that cuts on either
side of exon V, rendering a 1.1-kb
fragment. Lane 1, genomic DNA of
index case 1 evaluated with the
Ml (VaI213) Normal350356 probe. Lane 2, identi-
Ml (Val213) cal to lane I except evaluated with
the Nullmattw. probe. Lane 3, geno-
Normal mic DNA of index case 2 evaluated
350-356 Nullm with the Normal350356 probe. Lane
4, identical to lane 3 except evalu-
ated with the Nullmattawa probe.
Lane 5, genomic DNA of the father
of the index cases evaluated with
the Normal 350-356 probe. Lane 6,
identical to lane 5 except evaluated
with the Nullmattawa probe. Lane 7,
genomic DNA of MI (Val213) homo-
zygote control evaluated with the
Normal 350-356 probe. Lane 8,
identical to lane 7 except evaluated
7 8 with the Nullmatawa probe.
Nullma.n.. type to murine fibroblasts demonstrated that the
aIAT Null state associated with the Nullmant., gene could be
reproduced in cells that do not normally produce human pro-
teins, and do not normally produce any form ofaIAT (Fig. 7).
Cells modified to contain the normal alAT Ml(Val213)-type
cDNA exhibited human aIAT gene expression at the mRNA
and protein level. In contrast, whereas the cells modified to
contain the a lAT Nuilmaa,,a-type cDNA expressed equivalent
Ml (Vat213) Index
Ml (Vat213) case 2
1.8 kb.-
1
Figure 5. Northern analysis of
alAT transcripts in blood
monocytes of index case 2 and
Ml(Val213) homozygote con-
trol. Total cellular RNA (10
* zsg/lane) was evaluated using a
32P-labeled human alAT
cDNA probe. Lane 1,
MIl(Val2 3) homozygote. Lane
2, index case 2. The position
and average length of normal
Ml(Val213) alAT mRNA tran-
2 script is indicated.
amounts of alAT mRNA transcripts, no aIAT protein prod-
uct could be detected. In this regard, cytoplasmic dot analysis
ofRNA isolated from the cell populations using a 32P-labeled
a IAT cDNA probe demonstrated comparable levels of alAT
mRNA transcripts in the NIH-3T3/alAT-Ml and NIH-3T3/
alAT-Mattawa cells (Fig. 8 A). This finding is consistent with
the concept that the Nullmatawa alAT mRNA transcript has
comparable stability to the normal Ml(Val213) alAT mRNA
M1(Val213) Nulllan.,a Figure 6. In vitro translation of
Nullma.t,. and Ml(Val213) alAT
mRNA transcripts. Synthetic
alAT mRNA transcripts derived
by in vitro transcription of
Nullmatt,. and Ml(Val213) alAT-
kD type cDNAs, respectively, were
47-o- used to direct alAT protein syn-45-s- thesis in a rabbit reticulocyte ly-
sate system with [35S]methionine
as a label. Shown are fluorograms
of SDS-acrylamide gel analysis of
1 2 [35S]methionine-labeled alAT.
Lane 1, Ml(Val2 3) aIAT. Lane 2,
Nullmatt.w, alAT. The positions of the 47- and 45-kD primary trans-
lation products ofMI (Val213) and Nullmat,., mRNAs, respectively,
are indicated.
al-Antitrypsin NUllmatUaWa Gene 1149
pBR 322
S' LTR
300 bp
Figure 7. DNA plasmid map of the pN2-alAT/Ml and pN2-alAT/
Mattawa retroviral vectors containing full-length human a l -antitryp-
sin cDNAs of Ml-type and Nullma.,awa-type, respectively. The
pN2-alAT/Ml and pN2-alAT/Mattawa vectors were formed from
pN2 by combining (5'-3') the SV40 early promoter and the forward
orientation of the a1AT cDNAs of Ml(Val213) type and NUllmalwa
type, respectively, into the Xho I site. The Ml(Val2 3)-type and
Nullmatawa-type alAT cDNAs differ by a single-nucleotide insertion
causing the replacement of leucine by phenylalanine at amino acid
position 353 of the coded protein and a 3' frameshift with the genera-
tion of a premature stop codon at position 376.
transcript. However, despite the presence of a 1 AT mRNA
transcripts which differ from Ml(Val2"3) a lAT mRNA tran-
scripts by only a single nucleotide insertion, murine fibroblasts
containing the Nullmttaw5-type cDNA exhibited no detectable
human a IAT protein (Fig. 8 B). In this context, labeling with
[35S]methionine for 30 min followed by a 120-min chase
showed that the murine fibroblasts containing the Ml(Val213)-
type a lAT cDNA secreted a 52-kD mature form of human
a IAT specifically immunoprecipitated by anti-a lAT anti-
body (lane 1). In marked contrast, no secreted human aIAT
could be detected from the Nullmallwa cDNA-containing cells
(lane 2). Analysis of the cellular lysates after a 30-min pulse
labeling with [35S]methionine for the NIH-3T3/alAT-Ml
cells showed a 50-kD precursor form of human a1AT specifi-
cally immunoprecipitated by anti-a lAT antibody (lane 3). In
contrast, examination of lysates of NIH-3T3/alAT-Mattawa
cells demonstrated no detectable intracellular alAT (lane 4).
Thus, although it is conceivable that the truncated a 1AT pro-
tein associated with the Nullmallawa gene is stable but not de-
tected by the polyclonal anti-alAT antibody used, it is more
likely that if a truncated protein is produced, it is degraded
rapidly and thus not detected.
Discussion
Although the consequences of all a lAT Null alleles are identi-
cal, i.e., no detectable serum alAT, it is becoming apparent
that several different mutational events may render an a 1AT
gene Null. To date, all result from mutations in exons coding
for the mature form of the a lAT protein. Nullbewnam results
from a nucleotide substitution mutation in exon III, causing
the substitution of a stop signal for a lysine residue (Lys2"7
AAG -. stop2"7 TAG) (21). In contrast, NUll1granie fallsresults
from a single nucleotide deletion mutation in exon II at amino
acid position 160 causing a 5' frameshift of the reading frame
with the consequent generation of a premature stop signal at
the codon position of the mutation (Tyr'60TAC Val'6'GTG,
deletion ofC in codon TAC for residue 160, and 5' frameshift
forming stop160TAG) (22). The Nullhong kong allele is a TC dinu-
cleotide deletion at Leu318 causing a 5' frameshift with genera-
tion of a premature termination codon at position 334 (23).
The a 1AT Nullmaawa allele presents yet another mechanism; a
Null allele resulting from a single-nucleotide insertional muta-
tion within the coding region of exon V, causing a distal 3'
frameshift, differentamino acids substituting forresidues 353 -I
375, and a premature stop codon at residue 376. Thus, the
heterogeneity in the Null mutations is diverse. Consistent with
this concept, we have recently observed an entirely different
cause of the Null state, an inherited deletion of the entire
aIAT gene (NU1ldeleCim0 procida; Takahashi, H., and R. Crystal,
unpublished observation).
A
NIH-3T3
NIH-3T3/a1AT-Mi 9 @ *
NIH-3T3/a1AT-Mattawa *-**
B
Extracellular
NIH-3T3 NIH-3T3
a1 AT-MI al AT-Mattawa
kDa
52. Elms
1
Intracellular
NIH-3T3 NIH-3T3
a1AT-Mi a1lAT-Mattawa
kDa
50, * *
3 42
Figure 8. Evaluation of human alAT gene expression in murine fi-
broblasts modified to contain the a 1AT cDNAs ofMl(Val2'13)type
and Nullanw5-type. (A) Identification of alAT mRNA transcripts in
mouse fibroblasts containing the integrated Ml(Val2'13)-type and
Nullm.,w,-type human alAT cDNAs. Shown are data from
NIH-3T3/alAT-Ml and NIH-3T3/alAT-Mattawa cells and as con-
trol, unmodified NIH-3T3 cells. Cytoplasmic RNA was evaluated for
human a1AT mRNA transcripts using cytoplasmic dot hybridiza-
tion analysis with a 32P-labeled a 1AT cDNA probe. (B) Synthesis
and secretion ofhuman a 1AT by mouse fibroblasts modified to con-
tain the human alAT cDNAs ofMl(Val2'13)-type and Nufllmattwa-
type. Shown are fluorograms of SDS-acrylamide gel analysis of 35S-
labeled proteins isolated from lysates and supernatants ofNIH-3T3/
alAT-Ml and NIH-3T3/alAT-Mattawa cells (30 min pulse with
[35S]methionine and 120 min chase with label-free media) and im-
munoprecipitated with an anti-a 1AT antibody. Lysates were ana-
lyzed directly after the 30-min pulse period and supernatants after
the 120-min chase period. Lane 1, NIH-3T3/alAT-Ml, supernatant.
Lane 2, NIH-3T3/alAT-Mattawa, supernatant. Lane 3, NIH-3T3/
a1AT-M 1, lysate. Lane 4, NIH-3T3/alAT-Mattawa, lysate. The po-
sition of the 52-kD secreted form and 50-kD intracellular form of
alAT are indicated.
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Insertional mutations generating a Null state have been
described in other protein deficiency disorders. Subsets of the
130 thalassemia genes have been identified in ethnic Asian In-
dians and Chinese that result from different single nucleotide
insertional mutations within the coding region of the fl-globin
gene (39, 40). Recently, Hidaka and colleagues (41) have iden-
tified an insertional mutation in a splice junction in the
human adenine phosphoribosyltransferase gene, causing aber-
rant splicing. Interestingly, the inserted nucleotide resulting in
the Nullmataswa allele is a thymidine that occurs at the terminus
of a short polymeric sequence of repeating thymidines. This is
consistent with the observation in studies of bacteriophage T4
mutants that nucleotide insertion mutations generating fra-
meshifts generally occur in the setting of short repeating poly-
meric sequences (42-45), a phenomenon which has been ex-
plained on the basis of slippage mispairing during transcrip-
tional replication (42, 46). Consistent with this concept, a
tetrameric or pentameric polythymidine sequence has been
shown to be a frameshift mutational hot spot both in vivo (44,
45) and in in vitro systems evaluating mutagenesis (47, 48).
The insertional mutation of the Nullmauawa gene generates a
3' frameshift with an altered reading frame distal to and in-
cluding codon 353. This altered reading frame terminates at a
premature stop signal at new codon 376, 19 codons upstream
from the normal stop signal. Interestingly, the presence of a
premature stop signal in the Nullmatwa allele is associated with
a normal-sized a 1AT mRNA transcript. In contrast, the pre-
mature stop signal of Nullbeilingham is associated with the com-
plete absence of detectable aIAT mRNA from a lAT-express-
ing cells (20). Perhaps an explanation for this difference is that
the premature stop signal of the Nullbiingham allele occurs near
the center of the a IAT mRNA transcript; the lack of a IAT
mRNA in this setting may be the consequence ofmRNA mol-
ecules not protected at the 3' end by polysomes, as has been
proposed for some of the 130 thalassemia mutations in which
no f3-globin mRNA is detected (49, 50). In this regard, the
Nullmatuwa allele is associated with a premature stop signal near
the terminal part of the aIAT mRNA molecule. In this setting,
the occurrence of the stop signal at a distal position may allow
sufficient protection by polyribosomes such that a stable alAT
mRNA transcript results.
As the a lAT Nullmattawa allele is associated with a lAT
mRNA transcripts, it is of interest that no alAT translation
product in association with this allele could be detected from
cells with the Nullmattwa mutation. In vitro translation analysis
ofthe Nullmalawa mRNA transcript demonstrated that it directs
synthesis of a truncated a 1AT molecule. The coded transla-
tion product contains alterations of the primary protein struc-
ture predictive of structural instability (51). Presumably, the
conformational changes affected by these alterations generate
a protein species incapable of secretion. This could occur on
the basis of intracellular aggregation within a subcellular com-
partment or alternatively, secondary to intracellular degrada-
tion of the nascent protein. The alAT Nullhong kong gene has
recently been shown to result in a truncated a 1AT protein
which aggregates within the cell at the level of the rough endo-
plasmic reticulum (23). In contrast, not only can no alAT be
detected as a secretion product from a 1 AT-expressing cells
with the Nullmatwa gene, but additionally, no detectable intra-
cellular form of a lAT can be identified aggregating within the
cell. Thus, it is likely that translation of the NUllmattwa mRNA
results in synthesis of a structurally unstable, truncated a 1AT
molecule, with the consequence that the altered a IAT protein
is degraded within the cell and thus not present in the serum in
detectable amounts.
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